Tobias K Dallenga

Dr. Tobias K Dallenga

Research Center Borstel - Leibniz Lung Center
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Cell Host & Microbe
Verified
Journal Article
Closed access
TDTobias K Dallenga
Tobias K Dallenga
URUrska Repnik
Urska Repnik
BCBjörn Corleis
Björn Corleis
JEJacqueline Eich
Jacqueline Eich
RRRudolph Reimer
Rudolph Reimer
USUlrich Emil Schaible
Ulrich Emil Schaible

2 August 2010 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
TDTomasz Dziedzic
Tomasz Dziedzic
IMImke Metz
Imke Metz
TDTobias K Dallenga
Tobias K Dallenga
FKFatima Barbara König
Fatima Barbara König
SMSven Müller
Sven Müller
WBWolfgang Brück
Wolfgang Brück

1 February 2012 in NeuroImage
Verified
Journal Article
Closed access
SBSusann Boretius
Susann Boretius
AEAngelika Escher
Angelika Escher
TDTobias K Dallenga
Tobias K Dallenga
CWClaudia Wrzos
Claudia Wrzos
RTRoland Tammer
Roland Tammer
CSChristine Stadelmann
Christine Stadelmann

22 February 2016 in Pathogens and Disease
Verified
Journal Article
Closed access
PDF file
TDTobias K Dallenga
Tobias K Dallenga
USUlrich Emil Schaible
Ulrich Emil Schaible
Necrotizing granulomas, exacerbating pathogenesis and neutrophil influx at the site of infection are a hallmark of active pulmonary tuberculosis (TB) in humans. The role of polymorphonuclear neutrophils (PMN) in host defence and TB pathogenesis has recently attracted broader interest. Association of infiltrating PMN, enhanced mycobacterial load, and disease exacerbation in both, mice susceptible to experimental TB as well as in TB patients link PMN to exacerbated pathology. Targeting PMN resulted in smaller lung lesions and reduced mycobacterial burden. Therefore, PMN-associated molecules represent interesting biomarkers to determine TB severity and treatment success. More importantly, PMN are putative targets for host-directed therapies (HDT) in TB. Due to the rise of multi- and extensively drug-resistant M. tuberculosis isolates, HDT represent adjunct measures to support antibiotic treatment by ameliorating pathology and local host defences.

17 March 2017 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SSShailender Singh
Shailender Singh
TDTobias K Dallenga
Tobias K Dallenga
AWAnne Winkler
Anne Winkler
SRShanu Roemer
Shanu Roemer
BMBrigitte Maruschak
Brigitte Maruschak
CSChristine Stadelmann
Christine Stadelmann
Axonal damage and loss substantially contribute to the incremental accumulation of clinical disability in progressive multiple sclerosis. Here, we assessed the amount of Wallerian degeneration in brain tissue of multiple sclerosis patients in relation to demyelinating lesion activity and asked whether a transient blockade of Wallerian degeneration decreases axonal loss and clinical disability in a mouse model of inflammatory demyelination. Wallerian degeneration and acute axonal damage were determined immunohistochemically in the periplaque white matter of multiple sclerosis patients with early actively demyelinating lesions, chronic active lesions, and inactive lesions. Furthermore, we studied the effects of Wallerian degeneration blockage on clinical severity, inflammatory pathology, acute axonal damage, and long-term axonal loss in experimental autoimmune encephalomyelitis using Wallerian degeneration slow (Wld S ) mutant mice. The highest numbers of axons undergoing Wallerian degeneration were found in the perilesional white matter of multiple sclerosis patients early in the disease course and with actively demyelinating lesions. Furthermore, Wallerian degeneration was more abundant in patients harboring chronic active as compared to chronic inactive lesions. No co-localization of neuropeptide Y-Y1 receptor, a bona fide immunohistochemical marker of Wallerian degeneration, with amyloid precursor protein, frequently used as an indicator of acute axonal transport disturbance, was observed in human and mouse tissue, indicating distinct axon-degenerative processes. Experimentally, a delay of Wallerian degeneration, as observed in Wld S mice, did not result in a reduction of clinical disability or acute axonal damage in experimental autoimmune encephalomyelitis, further supporting that acute axonal damage as reflected by axonal transport disturbances does not share common molecular mechanisms with Wallerian degeneration. Furthermore, delaying Wallerian degeneration did not result in a net rescue of axons in late lesion stages of experimental autoimmune encephalomyelitis. Our data indicate that in multiple sclerosis, ongoing demyelination in focal lesions is associated with axonal degeneration in the perilesional white matter, supporting a role for focal pathology in diffuse white matter damage. Also, our results suggest that interfering with Wallerian degeneration in inflammatory demyelination does not suffice to prevent acute axonal damage and finally axonal loss.

11 December 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
USUlrich E. Schaible
Ulrich E. Schaible
LLLara Linnemann
Lara Linnemann
NRNatalja Redinger
Natalja Redinger
EPEmmanuel C. Patin
Emmanuel C. Patin
TDTobias K Dallenga
Tobias K Dallenga
The global tuberculosis epidemic is the most common cause of death after infectious disease worldwide. Increasing numbers of infections with multi- and extensively drug-resistant variants of the M. tuberculosis complex, resistant even to newly discovered and last resort antibiotics, highlight the urgent need for an efficient vaccine. The protective efficacy to pulmonary tuberculosis in adults of the only currently available vaccine, M. bovis BCG, is unsatisfactory and geographically diverse. More importantly, recent clinical studies on new vaccine candidates did not prove to be better than BCG, yet. Here, we propose and discuss novel strategies to improve efficacy of existing anti-tuberculosis vaccines. Modulation of innate immune responses upon vaccination already provided promising results in animal models of tuberculosis. For instance, neutrophils have been shown to influence vaccine efficacy, both, positively and negatively, and stimulate specific antibody secretion. Modulating immune regulatory properties after vaccination such as induction of different types of innate immune cell death, myeloid-derived suppressor or regulatory T cells, production of anti-inflammatory cytokines such as IL-10 may have beneficial effects on protection efficacy. Incorporation of lipid antigens presented via CD1 molecules to T cells have been discussed as a way to enhance vaccine efficacy. Finally, concepts of dendritic cell-based immunotherapies or training the innate immune memory may be exploitable for future vaccination strategies against tuberculosis. In this review, we put a spotlight on host immune networks as potential targets to boost protection by old and new tuberculosis vaccines.